Metoclopramidhydrochlorid Accord

Metoclopramide Hydrochloride, the active ingredient in Metoclopramidhydrochlorid Accord, is a dopamine antagonist (antiemetic) presented as an oral dosage form for oral use. It is indicated for nausea and vomiting associated with chemotherapy, postoperative states, gastroparesis and as an adjunct in gastro‑oesophageal reflux disease. GNH USA supplies Metoclopramidhydrochlorid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Metoclopramide Hydrochloride acts on the central chemoreceptor trigger zone and gastrointestinal motility to control emesis and improve gastric emptying. - Chemotherapy‑induced nausea and vomiting: reduces frequency and severity of episodes. - Postoperative nausea and vomiting: helps control symptoms after surgery. - Gastroparesis: enhances gastric motility and alleviates related discomfort. - Gastro‑oesophageal reflux disease (adjunct): supports reflux management by promoting gastric emptying.

Metoclopramide Hydrochloride may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or agitation - Diarrhoea - Headache - Dry mouth

Serious or Rare Side Effects: - Tardive dyskinesia (involuntary movements) - Neuroleptic malignant syndrome - Severe depression or suicidal thoughts - Seizures - Allergic reactions including anaphylaxis - Cardiac arrhythmias

Before initiating therapy, consider the following safety measures. - History of movement disorders: avoid in patients with prior tardive dyskinesia. - Depression or suicidal ideation: monitor mental health closely. - Renal impairment: dose adjustment may be required. - Duration of therapy: limit use to the shortest period necessary, generally not exceeding 12 weeks. - Concomitant dopamine‑blocking agents: assess risk of additive effects. - Store at room temperature: keep in the original container, protect from moisture and light.

Metoclopramide Hydrochloride can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive dopamine antagonism. - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (opioids, benzodiazepines): increased sedation. - Serotonergic agents (ondansetron, SSRIs): potential serotonin syndrome. - CYP2D6 inhibitors (fluoxetine, paroxetine): elevated metoclopramide levels.

Moderate Interactions (Monitor Closely): - Anticholinergics: may diminish pro‑kinetic effect. - CYP3A4 inducers (rifampin, carbamazepine): reduced efficacy. - NSAIDs: heightened risk of gastrointestinal irritation. - Diuretics: possible electrolyte disturbances. - Alcohol: may enhance central nervous system depression.